• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

J Clin Med . SARS-CoV-2: Repurposed Drugs and Novel Therapeutic Approaches-Insights Into Chemical Structure-Biological Activity and Toxicological Sc

tetano

Editor, Senior Moderator
J Clin Med


. 2020 Jul 2;9(7):E2084.
doi: 10.3390/jcm9072084.
SARS-CoV-2: Repurposed Drugs and Novel Therapeutic Approaches-Insights Into Chemical Structure-Biological Activity and Toxicological Screening


Cristina Adriana Dehelean[SUP] 1 [/SUP], Voichita Lazureanu[SUP] 2 3 [/SUP], Dorina Coricovac[SUP] 1 [/SUP], Marius Mioc[SUP] 1 [/SUP], Roxana Oancea[SUP] 4 [/SUP], Iasmina Marcovici[SUP] 1 [/SUP], Iulia Pinzaru[SUP] 1 [/SUP], Codruta Soica[SUP] 1 [/SUP], Aristidis M Tsatsakis[SUP] 5 [/SUP], Octavian Cretu[SUP] 2 [/SUP]



Affiliations

Abstract

SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) pandemic represents the primary public health concern nowadays, and great efforts are made worldwide for efficient management of this crisis. Considerable scientific progress was recorded regarding SARS-CoV-2 infection in terms of genomic structure, diagnostic tools, viral transmission, mechanism of viral infection, symptomatology, clinical impact, and complications, but these data evolve constantly. Up to date, neither an effective vaccine nor SARS-CoV-2 specific antiviral agents have been approved, but significant advances were enlisted in this direction by investigating repurposed approved drugs (ongoing clinical trials) or developing innovative antiviral drugs (preclinical and clinical studies). This review presents a thorough analysis of repurposed drug admitted for compassionate use from a chemical structure-biological activity perspective highlighting the ADME (absorption, distribution, metabolism, and excretion) properties and the toxicophore groups linked to potential adverse effects. A detailed pharmacological description of the novel potential anti-COVID-19 therapeutics was also included. In addition, a comprehensible overview of SARS-CoV-2 infection in terms of general description and structure, mechanism of viral infection, and clinical impact was portrayed.

Keywords: SARS-CoV-2; chloroquine; convalescent plasma; hydroxychloroquine; lopinavir/ritonavir; remdesivir.
 
Back
Top Bottom